http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011126254-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2009-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011126254-A |
| titleOfInvention | APPLICATION OF HSP90 INHIBITORS FOR THERAPEUTIC TREATMENT |
| abstract | 1. The use of an Hsp90 inhibitor for the manufacture of pharmaceutical compositions for use in the treatment of cancer of the bladder, colon and colon, rectum, liver, lung, chest, vagina, ovaries, pancreas, kidney, stomach, digestive tract, prostate, head and neck , skin, abdominal cavity, thyroid gland, bones, brain, central nervous system, endocrine system, thyroid gland, adrenal glands and / or blood, and / or myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multifocal oh Castleman's disease and / or psoriaza.2. The use according to claim 1, wherein the Hsp90 inhibitor is a compound of formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R is selected from the group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4 ) (C-C) alkoxy group, (5) thiol, (6) (C-C) alkylthiol, (7) substituted or unsubstituted (C-C) alkyl, (8) amino group or substituted amino group, (9) substituted or unsubstituted aryl, (10) substituted or unsubstituted heteroaryl and (11) substituted or unsubstituted heterocyclyl; R is selected from the group consisting of: (1) hydrogen, (2) substituted or unsubstituted (C-C) alkyl, (3) substituted or unsubstituted (C-C) alkenyl, (4) substituted or unsubstituted (C-C) alkynyl, (5) substituted or unsubstituted (C-C) cycloalkyl, (6) substituted or unsubstituted (C-C) cycloalkenyl, (7) substituted or unsubstituted aryl, (8) substituted or unsubstituted heteroaryl, and (9) substituted or unsubstituted heterocyclyl; R is selected from the group consisting of: (1) substituted or unsubstituted (C-C) cycloalkyl , (2) substituted or unsubstituted (C-C) cycloalkenyl, (3) substituted or unsubstituted aryl, (4) substituted or unsubstituted |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2656342-C2 |
| priorityDate | 2008-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.